Most Read Articles
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Jairia Dela Cruz, 23 Apr 2019
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.
02 Dec 2019
Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.
Pearl Toh, 20 Dec 2019
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.

Novel selective cathepsin K inhibitor safely reduces bone, cartilage progression in osteoarthritis

08 Jan 2020

The new selective cathepsin K inhibitor MIV-711 does not perform better than placebo in easing osteoarthritic pain, a study has shown. However, it substantially decreases bone and cartilage progression with a reassuring safety profile.

The MIV-711 showed no statistically significant changes in numerical rating scale (NRS) pain scores as compared with placebo (MIV-711 100 mg/d, –1.7; MIV-711 200 mg/d, –1.5; placebo, –1.4).

Nonetheless, its use resulted in a significant decrease in medial femoral bone area progression (p=0.002 for 100 mg/d; p=0.004 for 200 mg/d) and medial femoral cartilage thinning (p=0.023 for 100 mg/d; p=0.125 for 200 mg/d), as well as a substantial reduction in bone and cartilage biomarker levels.

Six participants experienced serious adverse events (three in the 100-mg/d group, two in the 200-mg/d group and one in the placebo group), but none of these events were treatment-related.

“This treatment may merit further evaluation as a disease-modifying osteoarthritis drug,” the authors said.

A total of 244 participants with primary knee osteoarthritis, Kellgren–Lawrence grade 2 or 3, and an nRS pain score of 4–10 were included in this 26-week randomized, double-blind, placebo-controlled phase IIa study with a 26-week open-label safety extension substudy.

Participants were randomly assigned to received MIV-700 100 (n=82) or 200 (n=81) mg daily, or matched placebo (n=77). Forty-six participants who initially received 200 mg/d and four who received placebo were given 200 mg of MIV-700 daily during the extension substudy.

The trial was limited by its relatively short duration.

“MIV-711 is a novel selective cathepsin K inhibitor with beneficial effects on bone and cartilage in preclinical osteoarthritis models,” according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Jairia Dela Cruz, 23 Apr 2019
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.
02 Dec 2019
Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.
Pearl Toh, 20 Dec 2019
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.